

## ABSTRAK

Penelitian ini bertujuan untuk menganalisis kinerja keuangan dan harga saham perusahaan farmasi yang terdaftar di Bursa Efek Indonesia (BEI) pada saat sebelum dan selama pandemi COVID-19. Penelitian ini menggunakan metode kuantitatif deskriptif dengan objek penelitian perusahaan farmasi yang terdaftar di BEI pada periode 2019 hingga 2021. Analisis kinerja keuangan dilakukan secara deskriptif dengan menggunakan rasio-rasio keuangan seperti *quick ratio*, *inventory turnover ratio*, *debt ratio*, dan *profit margin*. Sementara itu, analisis harga saham dilakukan secara deskriptif dengan melihat harga saham pada akhir 2019 hingga 2021. Hasil penelitian menunjukkan bahwa kinerja keuangan sepuluh perusahaan farmasi yang terdaftar di Bursa Efek Indonesia (BEI) pada saat sebelum dan selama pandemi COVID-19 tidak mengalami perbedaan signifikan, sedangkan harga saham sepuluh perusahaan farmasi tersebut mengalami perbedaan signifikan.

Kata kunci: kinerja keuangan, harga saham, perusahaan farmasi, pandemi COVID-19

## **ABSTRACT**

*This study aims to analyze the financial performance and stock prices of pharmaceutical companies listed on the Indonesia Stock Exchange (IDX) before and during the COVID-19 pandemic. This study uses descriptive quantitative methods with research objects of pharmaceutical companies listed on the Indonesia Stock Exchange in the period 2019 to 2021. Financial performance analysis is carried out descriptively using financial ratios such as quick ratio, inventory turnover ratio, debt ratio, and profit margin. Meanwhile, stock price analysis was carried out descriptively by looking at stock prices at the end of 2019 to 2021. The results showed that the financial performance of ten pharmaceutical companies listed on the Indonesia Stock Exchange (IDX) before and during the COVID-19 pandemic did not experience significant differences, while the stock prices of the ten pharmaceutical companies experienced significant differences.*

*Keywords: financial performance, stock price, pharmaceutical company, COVID-19 pandemic*